S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NYSE:BIO

Bio-Rad Laboratories (BIO) Stock Forecast, Price & News

$368.51
-3.85 (-1.03%)
(As of 06/5/2023 ET)
Compare
Today's Range
$362.67
▼
$375.66
50-Day Range
$364.34
▼
$486.40
52-Week Range
$344.63
▼
$572.70
Volume
278,986 shs
Average Volume
185,274 shs
Market Capitalization
$10.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$653.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Bio-Rad Laboratories MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
77.2% Upside
$653.00 Price Target
Short Interest
Healthy
1.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.54
Upright™ Environmental Score
News Sentiment
0.73mentions of Bio-Rad Laboratories in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$849,307 Sold Last Quarter
Proj. Earnings Growth
16.01%
From $14.12 to $16.38 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

42nd out of 985 stocks

Analytical Instruments Industry

4th out of 27 stocks

See Top Rated MarketRank™ Stocks Here

BIO stock logo

About Bio-Rad Laboratories (NYSE:BIO) Stock

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Stock News Headlines

June 3, 2023 | americanbankingnews.com
Bio-Rad Laboratories (NYSE:BIO) Sees Strong Trading Volume
June 2, 2023 | finance.yahoo.com
Bio-Rad Laboratories (BIO) Gains But Lags Market: What You Should Know
June 5, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
June 1, 2023 | finance.yahoo.com
Bio-Rad to Present Company Overview at Jefferies Healthcare Conference
May 31, 2023 | finance.yahoo.com
Is It Time To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
May 24, 2023 | americanbankingnews.com
Bio-Rad Laboratories (NYSE:BIO) Sees Large Volume Increase
May 20, 2023 | americanbankingnews.com
Bio-Rad Laboratories (NYSE:BIO) Earns Buy Rating from Analysts at StockNews.com
May 17, 2023 | marketwatch.com
Automated Blood Bank System Market Projected to Show Strong Growth by 2030| Grifols, Bio-Rad Laboratories, Inc, Immucor
June 5, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 16, 2023 | marketwatch.com
Label Free Detection Market Outlook 2023 and Forecast to 2030 | Ametek, Bio-Rad Laboratories, General Electric
May 16, 2023 | seekingalpha.com
Bio-Rad And Its Real Value
May 15, 2023 | marketwatch.com
Label Free Detection Market Next Big Thing With Major Giants Bio-Rad Laboratories, General Electric, Bioptix, Attana
May 11, 2023 | marketwatch.com
Label Free Detection Market Future Trends Demand 2023, and Forecast to 2030 | Ametek, Bio-Rad Laboratories, General Electric, X-body Biosciences
May 11, 2023 | marketwatch.com
Laboratory Temperature Control Units Market Outlook 2023 And Forecast To 2030 | AutoMate Scientific, Bio-Rad Laboratories, BMG Labtech
May 11, 2023 | finance.yahoo.com
Bio-Rad Laboratories First Quarter 2023 Earnings: EPS: US$2.33 (vs US$112 loss in 1Q 2022)
May 11, 2023 | marketwatch.com
Microparticle Chemiluminescence Reagent Market Overview and Detailed Business Analysis till 2030 | Bio-Rad Laboratories, Thermo Fisher Scientific
May 10, 2023 | nasdaq.com
Citigroup Maintains Bio-Rad Laboratories Inc. - (BIO) Buy Recommendation
May 10, 2023 | marketwatch.com
Digital PCR Instrument Market 2023 Technology Advancements and Research-Bio-Rad Laboratories, QIAGEN, Roche, Thermo Fisher Scientific
May 9, 2023 | marketwatch.com
Digital Polymerase Chain Reaction (dPCR) Market Hitting New Highs by 2030 | Thermo Fisher, Bio-Rad Laboratories,,
May 8, 2023 | finance.yahoo.com
Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference
May 5, 2023 | finance.yahoo.com
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down
May 5, 2023 | americanbankingnews.com
Zacks Research Weighs in on Bio-Rad Laboratories, Inc.'s Q1 2023 Earnings (NYSE:BIO)
May 4, 2023 | marketwatch.com
In Vitro Diagnostics (IVD) Market Business Scenario 2023-2030
May 4, 2023 | marketwatch.com
LFA-based Cardiac Marker Market 2023 to 2029 Industry Product and leading Companies – Thermo Fisher, Bio-Rad Laboratories, Becton
May 3, 2023 | finance.yahoo.com
Global Central Nervous System (CNS) Biomarkers Report 2023: Need to Reduce Drug Development Costs and Failures Drives Growth
May 3, 2023 | marketwatch.com
Legionella Routine Testing Market Rising Demand and Future Opportunities | Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories
May 3, 2023 | marketwatch.com
Agarose Market Drivers, Restraints, Size in terms of Volume and Value and Forecast 2023-2030 Lonza, Hispanagar, Bio-Rad Laboratories
See More Headlines

BIO Price History

BIO Company Calendar

Last Earnings
5/04/2023
Today
6/05/2023
Next Earnings (Estimated)
7/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NYSE:BIO
CUSIP
09057220
CIK
12208
Web
www.bio-rad.com
Phone
(510) 724-7000
Fax
510-741-5817
Employees
8,200
Year Founded
1952

Price Target and Rating

Average Stock Price Forecast
$653.00
High Stock Price Forecast
$700.00
Low Stock Price Forecast
$579.00
Forecasted Upside/Downside
+78.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($6.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
25.91
P/E Growth
N/A
Net Income
$-3,627,530,000.00
Net Margins
-7.01%
Pretax Margin
-9.05%
Return on Equity
4.10%
Return on Assets
2.91%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
5.56
Quick Ratio
4.28

Sales & Book Value

Annual Sales
$2.80 billion
Price / Sales
3.87
Cash Flow
$14.36 per share
Price / Cash Flow
25.48
Book Value
$324.89 per share
Price / Book
1.13

Miscellaneous

Outstanding Shares
29,610,000
Free Float
24,558,000
Market Cap
$10.83 billion
Optionable
Optionable
Beta
0.91

Social Links


Key Executives

  • Norman D. Schwartz
    Chairman, President & Chief Executive Officer
  • Andrew J. Last
    Chief Operating Officer & Executive Vice President
  • Ilan DaskalIlan Daskal
    Chief Financial Officer & Executive Vice President
  • Simon May
    Executive VP & President-Life Science Group
  • Timothy S. ErnstTimothy S. Ernst
    Secretary, Executive VP & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BIO Stock - Frequently Asked Questions

Should I buy or sell Bio-Rad Laboratories stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIO shares.
View BIO analyst ratings or view top-rated stocks.

What is Bio-Rad Laboratories' stock price forecast for 2023?

3 brokerages have issued twelve-month price targets for Bio-Rad Laboratories' shares. Their BIO share price forecasts range from $579.00 to $700.00. On average, they expect the company's stock price to reach $653.00 in the next year. This suggests a possible upside of 78.7% from the stock's current price.
View analysts price targets for BIO or view top-rated stocks among Wall Street analysts.

How have BIO shares performed in 2023?

Bio-Rad Laboratories' stock was trading at $420.49 on January 1st, 2023. Since then, BIO shares have decreased by 13.1% and is now trading at $365.40.
View the best growth stocks for 2023 here.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 291,200 shares, an increase of 23.2% from the April 30th total of 236,400 shares. Based on an average trading volume of 191,400 shares, the short-interest ratio is presently 1.5 days. Currently, 1.4% of the company's shares are sold short.
View Bio-Rad Laboratories' Short Interest.

When is Bio-Rad Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our BIO earnings forecast.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its quarterly earnings data on Thursday, May, 4th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.24 by $0.10. The medical research company earned $676.80 million during the quarter, compared to analysts' expectations of $689.28 million. Bio-Rad Laboratories had a negative net margin of 7.01% and a positive trailing twelve-month return on equity of 4.10%. The business's revenue for the quarter was down 3.3% on a year-over-year basis. During the same period last year, the company posted $4.94 earnings per share.
Read the conference call transcript.

What ETFs hold Bio-Rad Laboratories' stock?

ETFs with the largest weight of Bio-Rad Laboratories (NYSE:BIO) stock in their portfolio include Putnam BioRevolution ETF (SYNB), Harbor Health Care ETF (MEDI), ETFMG Treatments Testing and Advancements ETF (GERM), Principal Healthcare Innovators ETF (BTEC), Formidable Fortress ETF (KONG), Putnam Sustainable Future ETF (PFUT), First Trust Indxx Medical Devices ETF (MDEV) and Invesco S&P 500 Equal Weight Health Care ETF (RYH).

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.93 billion-$2.93 billion, compared to the consensus revenue estimate of $2.97 billion.

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.40%), Veritas Asset Management LLP (3.89%), State Street Corp (3.11%), Brown Advisory Inc. (2.86%), Bank of America Corp DE (1.55%) and Geode Capital Management LLC (1.50%). Insiders that own company stock include Ajit Ramalingam, Annette Tumolo, Giovanni Magni, Ilan Daskal, Michael Crowley, Timothy S Ernst and Timothy S Ernst.
View institutional ownership trends.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $365.40.

How much money does Bio-Rad Laboratories make?

Bio-Rad Laboratories (NYSE:BIO) has a market capitalization of $10.82 billion and generates $2.80 billion in revenue each year. The medical research company earns $-3,627,530,000.00 in net income (profit) each year or ($6.54) on an earnings per share basis.

How many employees does Bio-Rad Laboratories have?

The company employs 8,200 workers across the globe.

Does Bio-Rad Laboratories have any subsidiaries?
The following companies are subsidiares of Bio-Rad Laboratories: (f/k/a Bio-Rad Laboratories (Israel) Inc.), BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy), Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Rishon) Inc., Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Pasteur, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Biotest - Businesses, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, Ciphergen Biosystems - ProteinChip Systems Business, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., Dropworks Inc., GnuBIO Inc., Helix Diagnostics, IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, Propel Labs - Cell Sorting System Division, QuantaLife, Quantase Ltd., Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..
Read More
How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The official website for the company is www.bio-rad.com. The medical research company can be reached via phone at (510) 724-7000, via email at investor_relations@bio-rad.com, or via fax at 510-741-5817.

This page (NYSE:BIO) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -